Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone palmitate 6-month formulation versus 3-month formulation in schizophrenia
2017-001941-28Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2017
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of paliperidone palmitate in schizophrenia (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Time to relapse during the double-blind phase. Started Nov 2017; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2017-001941-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001941-28.